Design and synthesis of new potent dipeptidyl peptidase IV inhibitors with enhanced ex vivo duration

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 7, 2007, Pages 2631-2650

  Kondo, Takashi ^a   Nekado, Takahiro ^a   Sugimoto, Isamu ^a   Ochi, Kenya ^a   Takai, Shigeyuki ^a   Kinoshita, Atsushi ^a   Tajima, Yohei ^a   Yamamoto, Susumu ^a   Kawabata, Kazuhito ^a   Nakai, Hisao ^a   Toda, Masaaki ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

Author keywords

DPP IV inhibitor; Prolyl 2 cyanopyrrolidine

Indexed keywords

1 [[4 (1 AZEPANYLCARBONYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE; 1 [[4 (1 AZETIDINYLCARBONYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[4 (1 AZETIDINYLCARBONYL) 5 METHYL 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[4 (1 AZOCANYLCARBONYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[4 (1 PIPERIDINYLCARBONYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[4 (1 PYRROLIDINYLCARBONYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[4 (1,3 DIHYDRO 2H ISOINDOL 2 YLCARBONYL) 5 METHYL 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[4 (2 HYDROXYETHYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE[7,7 DIMETHYL 2 OXOBICYCLO[2.2.1]HEPT 1 YL]METHANESULFONATE; 1 [[4 (4 MORPHOLINYLCARBONYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[4 (4 THIOMORPHOLINYLCARBONYL) 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[4 (HYDROXYMETHYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[5 METHYL 4 (1 PYRROLIDINYLCARBONYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[5 METHYL 4 (4 MORPHOLINYLCARBONYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[5 METHYL 4 (4 THIOMORPHOLINYLCARBONYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 2 [5 [[2 CYANO 1 PYRROLIDINYL]CARBONYL] 3 PYRROLIDINYL] N,N DIMETHYLACETAMIDE 4 METHYLBENZENESULFONATE; 3 [5 [[2 CYANO 1 PYRROLIDINYL]CARBONYL] 3 PYRROLIDINYL] N,N DIMETHYLPROPANAMIDE 4 METHYLBENZENESULFONATE; 5 [[2 CYANO 1 PYRROLIDINYL]CARBONYL] 3 PYRROLIDINECARBOXAMIDE 4 METHYLBENZENESULFONATE; 5 [[2 CYANO 1 PYRROLIDINYL]CARBONYL] 3 PYRROLIDINYL ACETIC ACID 4 METHYLBENZENESULFONATE; 5 [[2 CYANO 1 PYRROLIDINYL]CARBONYL] N ETHYL 3 PYRROLIDINECARBOXAMIDE 4 METHYLBENZENESULFONATE; 5 [[2 CYANO 1 PYRROLIDINYL]CARBONYL] N ETHYL N METHYL 3 PYRROLIDINECARBOXAMIDE 4 METHYLBENZENESULFONATE; 5 [[2 CYANO 1 PYRROLIDINYL]CARBONYL] N ETHYL N,2 DIMETHYL 3 PYRROLIDINECARBOXAMIDE 4 METHYLBENZENESULFONATE; 5 [[2 CYANO 1 PYRROLIDINYL]CARBONYL] N METHYL 3 PYRROLIDINECARBOXAMIDE 4 METHYLBENZENESULFONATE; 5 [[2 CYANO 1 PYRROLIDINYL]CARBONYL] N PROPYL 3 PYRROLIDINECARBOXAMIDE 4 METHYLBENZENESULFONATE; 5 [[2 CYANO 1 PYRROLIDINYL]CARBONYL] N,N DIETHYL 3 PYRROLIDINECARBOXAMIDE 4 METHYLBENZENESULFONATE; 5 [[2 CYANO 1 PYRROLIDINYL]CARBONYL] N,N DIMETHYL 3 PYRROLIDINECARBOXAMIDE 4 METHYLBENZENESULFONATE; 5 [[2 CYANO 1 PYRROLIDINYL]CARBONYL] N,N,2 TRIMETHYL 3 PYRROLIDINECARBOXAMIDE 4 METHYLBENZENESULFONATE; BENZYL 1 ( TERT BUTOXYCARBONYL) 4 [(4 METHYLBENZENESULFONYL)OXY] 2 PYRROLIDINECSRBOXYLATE; BENZYL 1 (TERT BUTOXYCARBONYL) 4 CYANO 2 PYRROLIDINECARBOXYLATE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; EX VIVO STUDY; GLUCOSE BLOOD LEVEL; MONKEY; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIGENS, CD26; CHROMATOGRAPHY, THIN LAYER; DOGS; GLUCOSE TOLERANCE TEST; HUMANS; INDICATORS AND REAGENTS; MACACA FASCICULARIS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; OXIDATION-REDUCTION; PROTEASE INHIBITORS; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33847617068     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.01.041     Document Type: Article

References (20)

1. Heins J., Weiker P., Schonlein C., Born I., Hartrodt B., Neubert K., Tsuru D., and Barth A. Biochim. Biophys. Acta 954 (1988) 161
2. Hegen M., Niedobitek G., Clein C.E., Stein H., and Fleischer B. J. Immunol. 144 (1990) 2908
3. Deacon C.F., Hughes T.E., and Holst J.J. Diabetes 47 (1998) 764
4. Holst J.J., Orskov C., Nielsen O.V., and Schwartz T.W. FEBS Lett. 211 (1987) 169
5. Mentlein R., Gallwitz B., and Schmidt W.E. Eur. J. Biochem. 214 (1993) 829
6. Kieffer T.J., McIntosh C.H., and Pederson R.A. Endocrinology 136 (1995) 3585
7. Ahren B., Simonsson E., Larsson H., Landin-Olsson M., Torgeirsson H., Jansson P.A., Sandqvist M., Bavenholm P., Efendic S., Eriksson J.W., Dickinson S., and Holmes D. Diabetes Care 25 (2002) 869
8. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., Mangold B.L., Russell M.E., and Hughes T.E. J. Med. Chem. 46 (2003) 2774
9. Kim D., Wang L., Beconi M., Eiermann G.J., Fisher M.H., He H., Hickey G.J., Kowalchick J.E., Leiting B., Lyons K., Marsilio F., McCann M.E., Patel R.A., Petrov A., Scapin G., Patel S.B., Roy R.S., Wu J.K., Wyvratt M.J., Zhang B.B., Zhu L., Thornberry N.A., and Weber A.E. J. Med. Chem. 48 (2005) 141
10. Augeri D.J., Robl J.A., Betebenner D.A., Magnin D.R., Khanna A., Robertson J.G., Wang A., Simpkins L.M., Taunk P., Huang Q., Han S.P., Abboa-Offei B., Cap M., Xin L., Tao L., Tozzo E., Welzel G.E., Egan D.M., Marcinkeviciene J., Chang S.Y., Biller S.A., Kirby M.S., Parker R.A., and Hamann L.G. J. Med. Chem. 48 (2005) 5025
11. Sakashita H., Kitajima H., Nakamura M., Akahoshi F., and Hayashi Y. Biorg. Med. Chem. Lett 15 (2005) 2441
12. Tsai T.Y., Coumar M.S., Hsu T., Hsieh H.P., Chien C.H., Chen C.T., Chang C.N., Lo Y.K., Wu S.H., Huang C.Y., Huang Y.W., Wang M.H., Wu H.Y., Lee H.J., Chen X., Chao Y.S., and Jiaang W.T. Biorg. Med. Chem. Lett 16 (2006) 3268
13. Kondo, T.; Sugimoto, I.; Nekado, T.; Ochi, K.; Ohtani, T.; Tajima, Y.; Yamamoto, S.; Kawabata, K.; Nakai, H.; Toda, M. Bioorg. Med. Chem., in press, doi:10.1016/j.bmc.2007.01.033.
14. Kemp D.S., and Carter J.S. J. Org. Chem. 54 (1989) 109
15. Compound 64 was prepared by the following two methods. One of them is described in Section 2. The other is the same method as the reported one (Ezquerra et al. J. Org. Chem. 1995, 60, p 2925), which describes the established stereochemistry, starting with condensation reaction of the protected ethyl pyrroglutamate and 3-benzyloxypropionaldehyde. Products prepared by the above-described two methods showed an identical NMR. Based on the result, the stereochemistry of 4-position of 64 was determined to be 4β.
16. Bodco M.D., Johnstone A.N.C., Bazza G., Lopatriello S., and North M. Tetrahedron 51 (1995) 8545
17. Duke-Cohan J.S., Morimoto C., Rocker J.A., and Schlossman S.F. J. Biol. Chem 270 (1995) 14107
18. Iwaki-Egawa S., Watanabe Y., Kikuya Y., and Fujimoto Y. J. Biochem. 124 (1998) 428
19. Kudo M., Nakamura T., and Koyama J. J. Biochem. 97 (1985) 1211
20. Magnin D.R., Robl J.A., Sulsky R.B., Augeri D.J., Huang Y., Simpkins L.M., Taunk P., Betebenner D.A., Robertson J.G., Abboa-Offei B., Wang A., Cap M., Xing L., Tao L., Sitkoff D.F., Malley M.F., Gougoutas J.Z., Khanna A., Huang Q., Han S.-P., Parker R.A., and Hamann L.G. J. Med. Chem. 47 (2004) 2587